ebomi
Colour theme
Sign in
Insider · CIK 0001802528

Fairmount Funds Management LLC

CIK 0001802528 Name as filed on the most recent filing

Filed as Fairmount Funds Management LLC (25)

28 transaction lines · from 25 filings · filed 2021-09-23 to 2026-07-20 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.

How this page attributes a trade

A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.

01

Issuers this insider has filed against

Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-26 05:24 UTC.

No issuer is recorded

The catalog holds no filing linking this CIK to an issuer.

02

Transactions

Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.

5 transactions · Newest transaction date first, id breaking the tie.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-26 05:24 UTC.

Transactions filed by this insider
Direction Date Code Company Value USD Filing
2026-07-16 P, Open-market purchase Crescent Biopharma, Inc.CBIO 12,375,025, acquired Open Form 4 filing 0001104659-26-085113
2026-07-01 S, Open-market sale Oruka Therapeutics, Inc.ORKA 300,014,406, disposed Open Form 4 filing 0001104659-26-080009
2026-06-23 S, Open-market sale Spyre Therapeutics, Inc.SYRE 399,658,667, disposed Open Form 4 filing 0001104659-26-076967
2026-05-11 P, Open-market purchase Viridian Therapeutics, Inc.\DEVRDN 19,999,990, acquired Open Form 4 filing 0001104659-26-060294
2026-03-31 P, Open-market purchase Zenas BioPharma, Inc.ZBIO 3,000,000, acquired Open Form 4 filing 0001104659-26-038546
2026-03-31 S, Open-market sale Cogent Biosciences, Inc.COGT 242,620,000, disposed Open Form 4 filing 0001104659-26-038057
2026-01-22 S, Open-market sale Apogee Therapeutics, Inc.APGE 133,525,000, disposed Open Form 4 filing 0001104659-26-005921
2026-01-22 S, Open-market sale Cogent Biosciences, Inc.COGT 127,400,000, disposed Open Form 4 filing 0001104659-26-005924
2025-12-04 P, Open-market purchase Crescent Biopharma, Inc.CBIO 18,237,600, acquired Open Form 4 filing 0001104659-25-119320
2025-10-23 P, Open-market purchase Viridian Therapeutics, Inc.\DEVRDN 9,999,990, acquired Open Form 4 filing 0001104659-25-102606
2025-10-07 P, Open-market purchase Zenas BioPharma, Inc.ZBIO 6,008,161, acquired Open Form 4 filing 0001104659-25-098362
2025-07-10 P, Open-market purchase Cogent Biosciences, Inc.COGT 24,999,993, acquired Open Form 4 filing 0001104659-25-067758
2024-09-16 P, Open-market purchase Zenas BioPharma, Inc.ZBIO 5,100,000, acquired Open Form 4 filing 0001104659-24-100766
2024-09-16 P, Open-market purchase Zenas BioPharma, Inc.ZBIO 5,100,000, acquired Open Form 4 filing 0001104659-24-100330
2024-09-13 P, Open-market purchase Viridian Therapeutics, Inc.\DEVRDN 30,000,000, acquired Open Form 4 filing 0001104659-24-100769
2024-01-22 P, Open-market purchase Viridian Therapeutics, Inc.\DEVRDN 9,999,990, acquired Open Form 4 filing 0000950170-24-007123
2023-09-29 P, Open-market purchase Dianthus Therapeutics, Inc. /DE/DNTH 336,252, acquired Open Form 4 filing 0001104659-23-106378
2023-09-26 P, Open-market purchase Dianthus Therapeutics, Inc. /DE/DNTH 394,500, acquired Open Form 4 filing 0001104659-23-104808
2023-09-19 P, Open-market purchase Dianthus Therapeutics, Inc. /DE/DNTH 396,000, acquired Open Form 4 filing 0000899243-23-019370
2023-09-13 P, Open-market purchase Dianthus Therapeutics, Inc. /DE/DNTH 110,156, acquired Open Form 4 filing 0000950170-23-048022
2023-09-12 P, Open-market purchase Dianthus Therapeutics, Inc. /DE/DNTH 161,524, acquired Open Form 4 filing 0000950170-23-048022
2023-07-13 P, Open-market purchase Apogee Therapeutics, Inc.APGE 3 lines 49,999,992, acquired Open Form 4 filing 0001104659-23-081729
2023-06-09 P, Open-market purchase Cogent Biosciences, Inc.COGT 9,600,000, acquired Open Form 4 filing 0001104659-23-070794
2022-08-17 P, Open-market purchase Viridian Therapeutics, Inc.\DEVRDN 9,999,979, acquired Open Form 4 filing 0001104659-22-092992
2022-06-16 P, Open-market purchase Cogent Biosciences, Inc.COGT 9,900,000, acquired Open Form 4 filing 0001104659-22-072798
2021-09-21 P, Open-market purchase Viridian Therapeutics, Inc.\DEVRDN 9,999,000, acquired Open Form 4 filing 0000899243-21-037255

This column is intentionally blank

No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.

Search the catalog
Codes on this page
P, Open-market purchase
Open-market purchase
S, Open-market sale
Open-market sale
Relationships on this page
D, Director
Director
%, Ten percent owner
Ten percent owner

Every value is as reported on the Form 4, totalled to the dollar. Share counts, the price per share and the full list of reporting owners are on each filing's own page, which every row here opens. A row marked n lines adds up that many filed lines of one filing, on one day, on one side of the market; a filing whose lines fall across two pages is left as its lines on both, so no total here is ever short.

What this insider's stored lines contain

Exact counts over every stored line for this entity. This is a statement of composition, not a filter: the only filter this page offers is the open-market one above, because that is the only one an index serves today.

  • Open-market purchase 3
  • Open-market sale 2
  • Option exercise 0
  • Grant or award 0
  • Tax withholding 0
  • Disposition to the issuer 0
  • In-the-money option exercise 0

How to cite this page

ebomi catalog. Fairmount Funds Management LLC, insider transactions. Retrieved 2026-08-26 from https://ebomi.com/insider/0001802528

Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6

This page as JSON The JSON twin is shaped by the same read model as this page, so the two cannot disagree. Its envelope carries the canonical URL, the retrieval time, the coverage claim, and the licence statement.